CYTOKINETICS INC

For the period ended Mar 31, 2026. Filed May 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 5, 2026

CYTK$56.18+1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share data) (Unaudited)

	Three Months Ended
	March 31, 2026	March 31, 2025
Revenues:
Net product revenue	$4,789	$—
Collaboration revenues	2,637	1,579
License and milestone revenues	11,929	—
Total revenues	19,355	1,579
Operating expenses:
Research and development	95,525	98,262
Selling, general and administrative	104,896	57,369
Cost of goods sold	160	—
Collaboration cost of revenues	2,392	1,579
Total operating expenses	202,973	157,210
Operating loss	(183,618)	(155,631)
Interest and other expense, net	(14,519)	(8,868)
Non-cash interest expense on liabilities related to revenue participation right purchase agreements	(18,816)	(14,078)
Interest and other income, net	11,022	13,701
Change in fair value of derivative liabilities	1,500	(400)
Change in fair value of liabilities related to RPI Transactions	(1,600)	3,900
Net loss	$(206,031)	$(161,376)
Net loss per share — basic and diluted	$(1.67)	$(1.36)
Weighted-average number of shares used in computing net loss per share — basic and diluted	123,273	118,496
Other comprehensive (loss) gain:
Unrealized loss on available-for-sale securities, net	(1,838)	(541)
Foreign currency translation adjustments	(404)	(312)
Comprehensive loss	$(208,273)	$(162,229)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.